Floatz logo

Ibrutinib

Ependymoma

Theodore S. JohnsonSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

35 Active assets in the Ependymoma cohort.

Asset / SponsorPhaseRating
Nivolumab
University of Florida
Phase 2BB
Olaparib
Fundación de investigación HM
Phase 2BB
ETOPOSIDE
Theodore S. Johnson
Phase 2B
Indoximod
Theodore S. Johnson
Phase 2B
Cyclophosphamide
Theodore S. Johnson
Phase 2B

View all 50 →

Same molecule, other indications

Ibrutinib is also rated in:

lymphoid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
70 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →